Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

585
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
585
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

231
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
231
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retrospective Analysis of Inflammatory Biomarker Patterns and Platelet Dynamics in Hospitalized Adults.

International journal of general medicine·2026
Same author

Bioinformatic analysis reveals the potential association of ESRP1 with the splicing of cytoskeleton-associated genes in doxorubicin-resistant MCF7 breast cancer cells.

Discover oncology·2026
Same author

Amplification of heterogeneous nuclear ribonucleoprotein A/B aids in immune infiltration regulation and breast cancer tumorigenesis.

Experimental and therapeutic medicine·2026
Same author

ACY-1215 ameliorates experimental colitis by inhibiting dendritic cell maturation and Th1/Th17 responses.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2026
Same author

Avian coronaviruses induce inflammatory responses by activating p38/MAPK signaling and NLRP3/caspase-1 inflammasomes through sphingosine-1-phosphate receptor 1.

Veterinary research·2026
Same author

YTHDF2 promotes m6A-modified HSPA2 translation to restrict Newcastle Disease Virus.

Veterinary microbiology·2026
Same journal

Eravacycline in sepsis complicated by <i>Clostridioides difficile</i> infection: a brief case series.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Apatinib combined with capecitabine plus temozolomide versus sunitinib in advanced gastroenteropancreatic neuroendocrine tumours: a propensity score-matched real-world study.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Pharmacokinetic/pharmacodynamic optimization of antimicrobial therapy in neutropenic sepsis: a comprehensive review.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Cefiderocol for <i>Stenotrophomonas maltophilia</i> infections: real-world evidence from a multicenter study and a comprehensive literature review.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

Cefiderocol susceptibility in carbapenem-resistant <i>Acinetobacter baumannii</i>, <i>Pseudomonas aeruginosa</i>, and <i>Stenotrophomonas maltophilia</i> isolates: concordance of disk diffusion with the reference method and comparative analysis of CLSI-EUCAST criteria.

Journal of chemotherapy (Florence, Italy)·2026
Same journal

High-dose continuous infusion of piperacillin/tazobactam via elastomeric pump in a pediatric patient with Kartagener syndrome: pharmacokinetic target attainment and clinical outcome.

Journal of chemotherapy (Florence, Italy)·2026
See all related articles

Related Experiment Video

Updated: Aug 18, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K

Tigecycline treatment causes a decrease in peripheral blood platelet.

Yu Huang1, Libin Chen2, Handuo Su3

  • 1Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.

Journal of Chemotherapy (Florence, Italy)
|December 6, 2022
PubMed
Summary
This summary is machine-generated.

Tigecycline treatment for severe infections can decrease platelet counts, especially in older patients. This side effect is reversible upon discontinuing the antibiotic.

Keywords:
Tigecyclineantibioticsblood plateletelderlyinflammation indexesrisk factors

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K
Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
07:28

Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry

Published on: October 29, 2020

8.8K

Related Experiment Videos

Last Updated: Aug 18, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K
Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
07:28

Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry

Published on: October 29, 2020

8.8K

Area of Science:

  • Pharmacology
  • Hematology
  • Infectious Diseases

Background:

  • Tigecycline is a broad-spectrum antibiotic used for severe infections.
  • Increased tigecycline usage raises concerns about potential side effects.
  • The impact of tigecycline on platelet count requires further investigation.

Purpose of the Study:

  • To evaluate the effect of tigecycline on peripheral blood platelet counts in patients with severe infections.
  • To identify factors associated with tigecycline-induced thrombocytopenia.

Main Methods:

  • Retrospective analysis of demographic and laboratory data.
  • Inclusion of 24 patients treated with tigecycline for severe infections.
  • Monitoring of platelet counts before, during, and after tigecycline treatment.

Main Results:

  • 75% of patients (18/24) experienced a decrease in platelet count during tigecycline treatment.
  • The platelet decrease was more pronounced in older patients.
  • Platelet counts significantly dropped after 3 days of treatment and recovered within 5 days of discontinuation.

Conclusions:

  • Tigecycline treatment is associated with a significant decrease in platelet count in patients with severe infections.
  • Age is a potential risk factor for tigecycline-induced thrombocytopenia.
  • The observed platelet decrease is reversible upon tigecycline discontinuation.